THE PROJECT ALS APPROACH
Twenty years ago, Project ALS changed the way scientists and doctors conducted ALS research. As a result, we are closer to the first effective treatments for ALS.
The Project ALS business model—now widely adopted–requires that leading ALS researchers work together, share data openly, and meet shared deadlines. Project ALS works collaboratively with its scientists to identify the most promising ALS research and, along with its Research Advisory Board (RAB), streamlines the research process with effective strategies. Project ALS assesses progress through regular meetings and reviews by the RAB.
Project ALS engages in the ongoing recruitment of innovators, not only from neuroscience, but diverse disciplines including stem cell biology, mathematics, computation statistics, chemistry, bioimaging, and industry, to contribute to the growing body of knowledge of what goes wrong in ALS—and how we will fix it. Project ALS provides research funding on a rolling basis, ever poised to support innovation.
RESEARCH AND NEWS
- Prosetin receives Orphan Drug Designation from the US Food and Drug Administration
- Project ALS launches research partnership with Medidata Institute targeting new, actionable insights into ALS disease progression and subtypes
- Project ALS responds to challenges presented by the global COVID-19 pandemic and continues to move forward with new virtual fundraising efforts
- Project ALS announces prosetin, the first investigational drug to emerge from THE CORE as a potential treatment for ALS
- Jaci Hermstad receives first ever dose of jacifusen, a custom antisense oligonucleotide gene therapy to address Jaci’s genetic form of ALS
- Project ALS launches a free and open to the public webinar series featuring a range of experts for accessible, conversational updates covering research, hot topics in ALS drug development, and stories of people with ALS
- Pre-Clinical Core identifies several drugs of promise for ALS
- Project ALS celebrates 20th Anniversary. Over $90 million raised in 20 years with 89% going to research programs.
- Researchers funded reaches 95 at 35 institutions worldwide
- Project ALS Pre-Clinical Core at Columbia University Motor Neuron Center established
- Autophagy in ALS begins, a three-year study connecting researchers from Columbia, Cornell, UCSF, NYU and NY Genome Center
- Salk Institute researchers show that brain cells called interneurons contribute to ALS
- Don’t-Talk-a-Thon, the first Project ALS online fundraising campaign raises $600,000 and counting
- Establish Mass General/Project ALS Internship Program
- 26 ALS genes now identified
- RAB adds Nobel laureate as well as renowned experts from pharmaceutical/biotech, and neuroscience
- Basic studies at Columbia, Harvard, and Stanford show that brain cells called astrocytes are involved
- C9orf72 gene identified as having role in both familial and sporadic ALS
- Establish P2ALS, a $15 million partnership with Johns Hopkins, Dan Doctoroff and Michael Bloomberg
- Fund first multi-lab study focused on selective vulnerability of motor neurons in ALS
- Built first library of ALS patient cell lines, including those with genetic mutations
- Develop “ALS In a Dish” – a helpful new tool for studying human ALS.
- Women & the Brain starts; a Project ALS-created initiative to raise awareness for brain health and support for talented neuroscientists and need-based medical students with a focus on neurology.
- Project ALS/Jenifer Estess Laboratory for Stem Cell Research opens, the world’s first and only privately funded lab to focus exclusively on stem cells and ALS.
- Estess Lab team derives first functional human motor neurons from stem cells
- Researchers from Dalhousie University show that stem cell-derived motor neurons connect with and stimulate muscle.
- Jenifer Estess dies of ALS at age 40.
- First ALS specific gene therapy experiments at the Salk Institute. Treated mice survive 33.3% longer than untreated group.
- Original movie event Jenifer premiers on CBS and draws national attention to Project ALS
- Jenifer Estess named a Glamour Magazine’s “Women of the Year”. Project ALS named Vanity Fair’s “It List” charity.
- Scientists at Columbia University differentiate mouse stem cells into functional motor neurons, the very brain cells destroyed in ALS.
- At John Hopkins, rats with ALS-like syndrome recover significant motor function after stem cell treatment
- Jenifer Estess testifies before US Congress to the importance of federal funding for stem cell research in ALS
- Project ALS team at Mass General builds first standardized cell based-assay for rapid ALS drug testing
- First to study stem cells and ALS. Pilot studies at Children’s Hospital Boston and Johns Hopkins.
- Gala fundraisers in NY and LA unite entertainment and corporate communities
- Jenifer Estess diagnosed with ALS at 35. Jenifer, her sisters, and friends start Project ALS as the first 501(c)3 nonprofit dedicated solely to ALS research.
- Board of Directors and Research Advisory Board established
- First $1 million raised for collaborative experiments among scientists at Harvard University, Johns Hopkins, and Columbia University.